As wearables have increasingly become integrated into the medical landscape, digital endpoints have become an exciting new tool to support clinical trials. When implemented properly, digital endpoints have the potential to enhance any trial, whether observational or interventional, or early or late phase. Digital endpoints harness the data from sensors and other digital health technologies that are collected during an individual’s everyday life, allowing for the capture of existing measures in a new way.
A recent analysis found the use of connected digital products in clinical trials has grown since 2000, with a compound annual growth rate of about 34 percent. Most notably, in 2017 and 2018, alone, more than 1100 unique trials included the use of a connected digital product, a more than tenfold increase in their use when compared to the early 2000s (1), indicating the utility and benefits of using wearables and other digital technologies.
The data collected from these devices can be used as exploratory digital endpoints in early clinical studies, contributing to the evidence required to successfully develop them for use as primary or secondary endpoints in later trials. Below we discuss how digital endpoints can benefit any phase of clinical research.
Improved safety and efficacy for early phase clinical trials
Novel digital endpoints in phase II studies can prevent promising drugs from being terminated unnecessarily due to lack of evidence by measuring concepts that could not be previously assessed or were measured inadequately.
Through the use of wearables and remote patient monitoring, digital endpoints offer the ability to improve our understanding of the safety and efficacy profile of a drug, which may lead to greater success when going from phase II to phase III of a clinical trial (2). For example, a study released by Bellerophon Therapeutics described how a physical activity endpoint was evaluated in a phase II study and — following an agreement with the FDA — how that same endpoint will be used as a primary endpoint in the company’s upcoming pivotal phase III study (3).
Confident and efficient decision-making in late phase clinical trials
While traditional endpoints are still necessary for FDA submission and regulation, digital endpoints and biomarkers can provide sponsors with contextual information to arrive at go/no go decisions confidently and efficiently. Similar to early phase clinical trials, novel digital biomarkers can also be used in a phase III study to monitor outcomes, and could indicate a failure that might otherwise go undetected using traditional endpoints.
Additionally, using frequent and continuous monitoring can supplement or replace observational assessments, offering the possibility of more precise and accurate assessments (4). For example, a smart device could measure coughing, instead of relying on a patient to record episodes of coughing in a diary. In another instance, blood pressure, which is traditionally captured in a clinic, could be captured in a home environment using a connected digital blood pressure monitor.
This collection of real-world evidence to inform digital endpoints can be applied to post-market approvals, extensions of patents and trials for multipurpose drugs. In addition, the data collected can improve our understanding of how new therapies affect daily life activities, such as the ability to go grocery shopping or walk up and down stairs.
A study with digital endpoints is a patient-centric study
Over the past several years, the patient voice has been given greater weight, not only in the design of studies but also in terms of trial preferences, thereby increasing patient centricity. For patients, the use of digital health technologies can decrease the burden of trial participation by fostering remote monitoring and encouraging enrollment for potential participants who may have been unable to enroll previously due to socioeconomic factors or travel limitations.
This is reflected in a CTTI study where the majority of respondents (76 percent), with a median age of 61 years, reported they would prefer to participate in a decentralised study using mobile devices over a traditional one, citing greater convenience and fewer in-person visits (5). Further, respondents reported they were willing to use a variety of technologies — including mobile apps, wearable devices and ingestible sensors — provided they were comfortable, convenient and easy to use, demonstrating that using digital health technologies can increase patient engagement and retention.
More importantly, with the current pandemic, it may be necessary to use wearables and remote monitoring for those patients who are immuno-compromised. Using digital endpoints places the patient at the center of a clinical trial, as endpoints need to be clinically significant and meaningful to individuals.
Therefore, the integration of digital health technologies into trial design starts with choosing the necessary digital endpoints. Combining the experience of a dedicated digital health technology team and patient-centred scientists can help sponsors develop a framework to map the process from device selection to digital endpoint validation.
ICON has conducted almost 50 studies across all phases using digital health technologies. To learn more about our framework for successful implementation, along with the critical role of digital endpoints, read our white paper — Advancing digital endpoints: An end-to-end approach to managing wearable devices through clinical development.
References:
Marra, C., Chen, J.L., Coravos, A. et al. Quantifying the use of connected digital products in clinical research. npj Digit. Med. 3, 50 (2020). https://doi.org/10.1038/s41746-020-0259-x
CTTI Recommendations: Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials. (2017). Clinical Trials Transformation Initiative. https://www.ctti-clinicaltrials.org/files/novelendpoints-recs.pdf
Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis. (March 2020). https://www.globenewswire.com/news-release/2020/03/10/1997977/0/en/Bellerophon-Announces-Agreement-with-the-FDA-on-its-Planned-Pivotal-Phase-3-Study-for-the-Treatment-of-Pulmonary-Hypertension-Associated-with-Pulmonary-Fibrosis.html
Coravos, A., Khozin, S. and Mandl, K.D. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. npj Digit. Med. 2, 14 (2019). https://doi.org/10.1038/s41746-019-0090-4
Perry, B., Geoghegan, C., et al. (2019). Patient preferences for using mobile technologies in clinical trials. Contemporary Clinical Trials Communications. 15. https://doi.org/10.1016/j.conctc.2019.100399
Decentralized & Hybrid Trial Insights
ICON's Decentralised & Hybrid clinical trial experts provide analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of decentrilisation in clinical trials.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel